君聖泰醫藥-B(02511.HK)計劃將業務佈局擴展至河北省
君聖泰醫藥-B(02511.HK)公布,計劃將業務佈局擴展至河北省。目前,公司在深圳、上海、南昌和香港設有辦事處和研發中心。通過在河北省的業務佈局擴展,期望可吸引華北地區具有強大學術背景及行業經驗的人才加入,以進一步加強及豐富行業及監管註冊資源或原材料的供應能力,可能採取的業務擴展措施包括設立新的華北合作規劃、註冊事務管理或原材料生產營運基地。
上述業務擴展提議與公司進一步在中國促進其核心產品藥物開發、生產或商業化方面的戰略合作與夥伴關係的承諾相契合。公司認為,上述業務擴展提議將使公司能夠充分利用華北地區資源。(cy/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.